Terms: = Ovarian cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
33 results:
1. Mass Spectrometry-Based Proteomics of Epithelial ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
2. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
Sánchez-Fdez A; Matilla-Almazán S; Montero JC; Del Carmen S; Abad M; García-Alonso S; Bhattacharya S; Calar K; de la Puente P; Ocaña A; Pandiella A; Esparís-Ogando A
Clin Transl Med; 2023 Apr; 13(4):e1217. PubMed ID: 37029785
[TBL] [Abstract] [Full Text] [Related]
3. NOTCH Signaling Limits the Response of Low-Grade Serous ovarian cancers to MEK Inhibition.
Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
[TBL] [Abstract] [Full Text] [Related]
4. Flavonoids Restore Platinum Drug Sensitivity to ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract] [Full Text] [Related]
5. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract] [Full Text] [Related]
6. Dietary compound glycyrrhetinic acid suppresses tumor angiogenesis and growth by modulating antiangiogenic and proapoptotic pathways in vitro and in vivo.
Li J; Tang F; Li R; Chen Z; Lee SM; Fu C; Zhang J; Leung GP
J Nutr Biochem; 2020 Mar; 77():108268. PubMed ID: 31830590
[TBL] [Abstract] [Full Text] [Related]
7. Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways.
Zhang X; Hou G; Liu A; Xu H; Guan Y; Wu Y; Deng J; Cao X
Cell Death Dis; 2019 Oct; 10(10):770. PubMed ID: 31601793
[TBL] [Abstract] [Full Text] [Related]
8. Zamzam water protects cancer cells from chemotherapy-induced apoptosis via mitogen-activated protein kinase-dependent pathway.
Siraj AK; Begum R; Melosantos R; Albalawy W; Abboud J; Siraj N; Al-Kuraya KS
Biomed Pharmacother; 2019 Oct; 118():109376. PubMed ID: 31545262
[TBL] [Abstract] [Full Text] [Related]
9. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract] [Full Text] [Related]
10. Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of mek1/2 and Src signaling pathways.
Fang D; Chen H; Zhu JY; Wang W; Teng Y; Ding HF; Jing Q; Su SB; Huang S
Oncogene; 2017 Mar; 36(11):1546-1558. PubMed ID: 27617576
[TBL] [Abstract] [Full Text] [Related]
11. Long non-coding RNA MALAT1 is up-regulated in ovarian cancer tissue and promotes SK-OV-3 cell proliferation and invasion.
Zou A; Liu R; Wu X
Neoplasma; 2016; 63(6):865-872. PubMed ID: 27565324
[TBL] [Abstract] [Full Text] [Related]
12. Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.
McLachlan J; Gore M; Banerjee S
Pharmacogenomics; 2016 Aug; 17(12):1353-63. PubMed ID: 27469379
[TBL] [Abstract] [Full Text] [Related]
13. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous ovarian cancer.
Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
[TBL] [Abstract] [Full Text] [Related]
14. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract] [Full Text] [Related]
15. Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
Tolcher AW; Khan K; Ong M; Banerji U; Papadimitrakopoulou V; Gandara DR; Patnaik A; Baird RD; Olmos D; Garrett CR; Skolnik JM; Rubin EH; Smith PD; Huang P; Learoyd M; Shannon KA; Morosky A; Tetteh E; Jou YM; Papadopoulos KP; Moreno V; Kaiser B; Yap TA; Yan L; de Bono JS
Clin Cancer Res; 2015 Feb; 21(4):739-48. PubMed ID: 25516890
[TBL] [Abstract] [Full Text] [Related]
16. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral mek1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Bedard PL; Tabernero J; Janku F; Wainberg ZA; Paz-Ares L; Vansteenkiste J; Van Cutsem E; Pérez-García J; Stathis A; Britten CD; Le N; Carter K; Demanse D; Csonka D; Peters M; Zubel A; Nauwelaerts H; Sessa C
Clin Cancer Res; 2015 Feb; 21(4):730-8. PubMed ID: 25500057
[TBL] [Abstract] [Full Text] [Related]
17. mek1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract] [Full Text] [Related]
18. Differential outcome of mek1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells.
Cossa G; Lanzi C; Cassinelli G; Carenini N; Arrighetti N; Gatti L; Corna E; Zunino F; Zaffaroni N; Perego P
Cancer Lett; 2014 Jun; 347(2):212-24. PubMed ID: 24576622
[TBL] [Abstract] [Full Text] [Related]
19. mek1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract] [Full Text] [Related]
20. Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways.
Wang Z; Hou J; Lu L; Qi Z; Sun J; Gao W; Meng J; Wang Y; Sun H; Gu H; Xin Y; Guo X; Yang G
PLoS One; 2013; 8(11):e79117. PubMed ID: 24244431
[TBL] [Abstract] [Full Text] [Related]
[Next]
